旭輝控股集團(00884.HK)擬發行不多於50億元中期票據獲准註冊
格隆匯2月24日丨旭輝控股集團(00884.HK)公吿,公司於中華人民共和國註冊成立的全資附屬公司旭輝集團股份有限公司接獲由中國銀行間市場交易商協會發出日期為2022年2月11日的《接受註冊通知書》(中市協注[2022]MTN87號)("該通知書"),內容關於擬由旭輝中國於中國發行本金總額不多於人民幣50億元的中期票據經已獲准註冊。
前述的中期票據註冊額度自該通知書日期起計兩年內有效。旭輝中國可在註冊有效期內分期發行中期票據。該發行完成後,旭輝中國應通過交易商協會認可的途徑披露發行結果。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.